KDR and neoplasm: In addition, sunitinib, a marketed drug inhibiting tyrosine kinases by targeting not only VEGFR2 but also other RTKs (EGFR, PDGFR, and FGFR), was selected as a reference compound for comparing the potency on angiogenesis and tumor suppression with voacangine [26,27,28,29].